9/3/2014, DEA to scrutinize hospital pharmacists for opioid monitoring


“For example, in September 2013, FDA issued new labeling for long-acting and extended-release opioids, requiring that these drugs be used only for severe pain by patients needing continuous daily treatment over the long term and for whom alternative treatments are not adequate.”

Meet your new doctors:  the DEA and the FDA.

If you don't comment, I'll just assume you agree with me

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s